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Abstract
Palindromic rheumatism is a syndrome characterized by recurrent, self-resolving, 
and inflammatory attacks in and around the joints that have long recognized association 
with rheumatoid arthritis. PR attacks mostly start in small joints i.e. knees, shoulder, 
and small joints of the hand. Whether PR should be considered as a single disease or 
prodrome of RA remains a thought-provoking question. Multiple genetic and environ-
mental factors contribute to the development of PR. Many studies have explained the 
relationship between a high concentration of Anti-CCP antibodies and PR. Potential 
benefits of Gold therapy have been recognized in literature but still, there are some 
questions about toxicity and efficacy that need further considerations. In addition to 
that anti-malarial drugs, Abatacept, Tofacitinib, and Rituximab showed the variable 
result in different patients and needed further study to validate their medical use. 
Moreover, yarrow, oat, colchicum, dill, fennel, wild rue, bitter melon, willow, garlic, and 
burdock seem suitable candidates to treat rheumatoid although their use in PR is still not 
reported. Additional experimental researches on these drugs lead to an increase in our 
knowledge to fight against PR in the future using novel therapeutic approaches. We have 
attempted to cover this topic in a chapter form to provide a comprehensive view and 
hope that it will serve as a reference for clinicians who treat patients with PR.
Keywords: palindromic rheumatism, rheumatoid arthritis, environmental risk 
factors, genetic risk factors, therapies
1. Introduction
Palindromic rheumatism constitutes episodic and recurrent attack of articular 
inflammation that lasts from a few hours to several days which conclude without 
residual joint damage [1]. PR tends to affect small joints mostly, so the Knees, 
Shoulder, and small joints of hands are more prone to attack. Characteristic symp-
toms of PR include pain, swelling, redness, and disability of joints. This idiopathic 
condition was firstly described by Hench and Rosenberg in 1944 [2–6].
Distinctive features of PR include reoccurrence of attack at regular intervals and 
symptoms-free periods between attacks. Several studies have shown that about half of 
patients with PR develop Rheumatoid Arthritis (RA) and other joint diseases in later 
life [7]. PR is a single disease or spectrum of RE a leading question that is unanswered 
for 70 years. However, the target tissues are mostly the same in PR and RA [6, 8]. 
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A high concentration of Rheumatoid factor and Anti -CCP antibodies in both PR and 
RA strengthen the correlation between the two diseases. However, despite these simi-
larities, PR is different from RA in that joints are free of symptoms between attacks. 
According to research attacks of PR usually affect one joint but other structures can 
be affected in 30% cases and Rheumatoid nodules also appear in one-third cases of 
PR. Time of attack is not definite however according to Research in London 50% of 
patients develop attack of PR in the late afternoon and some others at night time [7–9].
2. Epidemiology
Indeed mounting studies highlight the frequency of PR is significantly lower 
than RA [9]. Epidemiological data from Canadian research suggest that females are 
most likely to develop PR than men in both conditions of Arthritis. However, it has 
been estimated that the average age was 56 years in RA and 49 in PR [10].
3. Etiology
Etiological factors for PR are under investigation and uncertain however 
intrinsic (gene mutations), extrinsic (external factor lifestyle and smoking) and 
idiopathic factors seem to be important in PR. Initially, it was believed that allergic 
agents and infectious agents may provoke the symptoms, but recent studies have 
shown that even the injection of histamine did not cause PR. It is thought that 
trauma, stress, anxiety, and cold can stimulate the flares of PR however recent data 
support the thought. Consumption of nitrate-containing food triggers PR [11].
Several etiological studies suggested that the mutated MEFV Gene seems to 
be an aggregating factor for the severity of PR [12]. According to Iranian research 
during the attack of PR level of C-reactive protein was increased in about 50%of 
cases. Erythrocyte sedimentation rate was also elevated during the attack of PR [13]. 
Anti-CCP antibodies level was also found high in PR patients [3, 14]. Another study 
showed that autoantibodies RF and anti-CCP concentration appear to be elevated in 
PR patients and is thought to be responsible for developing RA and other connective 
tissue diseases [15]. Further research conducted in PR patients also showed uplift RF 
concentration in 33.3% of patients and a high concentration of anti-CCP in 38.9% of 
patients. Another research showed the follow-up of 43 patients to other connective 
tissue diseases and of 28 patients to RA out of a total of 160 patients of PR [16, 17]. 
The recently high concentration of anti-CCP antibodies and anti-keratin was found 
in the patients of PR [11]. Studies have documented that ultrasonography of syno-
vitis of PR patients showed a high concentration of ACPA antibodies in PR patients. 
These studies suggest the strong relationship between Anti-Cyclic Citrullinted 
Protein antibodies and Rheumatoid factor in PR and RA [17–19].
Another report has elucidated the role of the HLA Gene on Chromosome 6 
which is thought to be responsible for about 30% of all cases of RA [20–22]. It is also 
reported that the HLA-DRB1 alleles encode for a shared epitope [10] which may be 
a risk factor for PR and RA [23]. Recent studies also showed a strong prevalence of 
HLA-DR shared epitope alleles in PR. The homozygosity of SE alleles in PR patients 
is responsible for the progress of half of the PR cases to RA. A Korean study showed 
a great prevalence of HLA-DRB1*0803 and HLA-DRB1*1302 in PR patients and 
these alleles are distinct in PR [24].
Many investigations have concluded that gene involvement in gene–environment 
interaction is not only one factor for a mutation in HLA-DRB1 but factors affecting 
gene linkage equilibrium may also cause variation in the gene [25].
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Other researchers have demonstrated the role of PADI4 (Protein-arginine 
deiminase type-4) which is a gene that encodes for enzymes that are responsible 
for the formation of Citrulline from arginine. It has recently been found that any 
effect in the stability of PADI4 results in a high level of Anti-CCP antibodies [26]. 
According to a Chinese study, periodic and episodic attacks of PR show a strong 
link with PADI4 [18, 22, 26].
TNFα (Tumor Necrosis factor) which are short-lived pro-inflammatory 
cytokines showed a strong relationship with PR. Another case study investigated 
TNFRSF1A and TNFRSF1B mutations in PR patients in the Chinese population 
[27, 28]. Another novel study has indicated that the concentration of cytokines 
like IL-6 and TNFα was elevated in synovium and serum of patients [29, 30]. It 
has been reported that TNFα microsatellite polymorphism indicates a close con-
nection with the disease by its association with HLA-DRB1 SE. Autoinflammatory 
diseases like PR are caused by deregulation in inflammasome components [31]. 
According to Novel research, the PYCARD\ASC Splice variant has been found in 
PR patients. This inflammasome-associated mutation may be a risk factor for PR 
patients. According to this research exon2, PYCARD\ASC is more expressed in 
patients with PR. PYCARD\ASC mature IL-IB for innate immunity. The inflex-
ibility of PYCARD\ASC leads to more secretions of IL-IB so the exon2 splice variant 
may be a risk factor for disease in PR patients [32]. The presence of conserved 
exon2 in DNA of all patients of PR, high amount of NLRP3 (Nucleotide-binding 
oligomerization domain, Leucine-rich Repeat, and Pyrin domain), and high 
concentration of IL-1B and IL-18 show the strong association between PR and this 
gene [33]. Comprehensive pathophysiology of Palindromic rheumatism has shown 
in Figure 1.
Polymorphism in the promoter sequence of Stromelysin 1(MMB- gene) and 
HLA gene have been studied in recent years. Recent studies indicated a close 
Figure 1. 
Overviews of Palindromic rheumatism.
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association between MEFV and PR. Another research investigated that smoking 
and PTPN22 Showed an association with an increase in ACPA. It is also reported 
that PTPN22 (Protein Tyrosine Phosphatase Non-receptor Type 22) which encodes 
for protein tyrosine phosphate clearly shows an association of microsatellite STP 
PTPN22gene with rheumatism [34]. According to a Chinese report Anti-MCV (Anti 
Mutated Citrullinated Vimentin) antibodies have also been reported as a biomarker 
in patients with Rheumatoid Arthritis although their role in PR is not studied [35] 
(Table 1).
4. Environmental factors
In recent year’s association of periodontitis (PD) and PR association has 
been studied. PD is inflammation of periodontal tissues caused by red-complex 
bacteria i.e.P.gingivalis which affects the process of Citrullination by expressing 
peptidyl- arginine deiminase enzyme (PAD) [38]. According to research in Israel 
avoiding offending diet and intake of proper diet may affect the flares of PR. 
Smoking can also trigger the process of Citrullination by affecting the immune 
reactions of the HLA Gene [39]. Most of the case study reports that the onset of 
Disease Clinical characteristics Gene mutation References
Gout (Urate crystals 
deposing disease)
Presence of needle-like crystals 




Reactive Arthritis Infections history in 
genitourinary and 
Gastrointestinal tract (GI)








Whipple’s disease Weight loss, diarrhea, and fever 








Sarcoidosis Granuloma formation and the 
possibility of erosive bone lesion
HLA-DRB1 Involvement [37]






Familial history, MEFV 
mutation, Chronic arthritis 
(5%)
MEFV mutation [37]
TRAPS Autosomal dominant TNF alpha [37]





No inflammatory sign MEFV involvement [37]
Relapsing 
polychondritis




Palindromic rheumatism and other relapsing diseases.
5
Palindromic Rheumatism: Biology and Treatment Options
DOI: http://dx.doi.org/10.5772/intechopen.96796
PR frequently begins in the late afternoon and early morning [40, 41]. Several 
factors responsible for the progression of PR as shown in Figure 2.
5. Palindromic rheumatism and diet
It has been observed that certain types of food can trigger a periodic attack 
of Palindromic rheumatism and elimination of that type of food from the diet 
has resulted in a reduction of attacks. According to a clinical trial conducted for 
evaluation of the role that certain type of food can play in PR, patients show that 
patients who were offended to eat eggs, cheese, fish, and canned vegetables resulted 
in the complete cessation of attack, and those patients who were presented with 
these food show more reoccurrence of attack. Therefore, offending food should 
be avoided to reduce the occurrence of PR although this needs more research that 
which type of specific food should be avoided [4, 42].
6. PR progression to RA
According to research in Japan, Anti-CPA in PR patients who developed RA 
was higher than those who did not develop RA in a future life [15]. According to a 
British case study of 39 patients of PR 19 showed progression to RA. Another study 
also indicated that most cases of PR progressed to other chronic arthritis and 35\60 
progressed to RA [43]. The reason for this progression is multifactorial and one of 
the factors for this progression is a misdiagnosis of PR as there is no specific test and 
diagnosis is made mostly on physician’s judgment and others may include progres-
sion duration which may vary from months to20 years [14, 44, 45].
Figure 2. 
Schematic representation of factors for development of Palindromic Rheumatism.
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7. Treatment options for PR
There is no specific treatment for PR for several reasons described earlier. 
Research has reported Non- Steroidal anti-inflammatory drugs appeared to delay 
flares of PR. In recent years Gold therapy is emerging as a promising treatment 
option for relieving joint pain and swelling. According to a study, about 60% of 
patients showed an improved result of gold salt. However, other studies have 
reported a high mucocutaneous side effect of gold therapy [8, 46]. The use of sul-
fasalazine also proves to be good for treating episodic flares of PR. In another study 
use of Chloroquine marked good results in the severity of an attack of PR where 
41 patients out of 51 showed improvement [47]. Another study also focused on the 
delay effect of antimalarial drugs in PR flares [48]. Antimalarial drugs prove to be 
good in treating PR by their inhibitory effect on TNFα and IL-1. The case of the 
application of antimalarial in 71 patients mostly showed good results by decreasing 
flares of PR [47].
According to recent research PR patients who did not respond well to drugs 
mostly use in PR showed a very good response to Rituximab [49]. Biological 
DMARDs (Abatacept) affect the immune system by inhibiting T-cells stimulation 
and prove to be good for patients who poorly respond to methotrexate. Tofacitinib 
is also used in patients of PR who poorly or intolerantly respond to DMARDS [50]. 
The possible treatment options are shown in Figure 3.
According to research in Japan successful use of Kampo therapy (a Chinese 
herbal medicine) in three patients with Rheumatoid reveal its pharmaceutical 
potential in treating rheumatism although it needs a deep study of these findings 
to uncover its biological potential [51]. According to research in Iran yarrow, oat, 
colchicum, dill, fennel, wild rue, bitter melon, willow, garlic, and burdock help 
treat rheumatoid although their use in PR is still not reported [52]. Heat therapy is 
a medication-free way to relieve muscle pain and stiffness and is also recommended 
to treat PR [41].
Figure 3. 
Possible treatment options for PR.
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8. Conclusion
Several risk factors such as genetic and environmental factors favor PR develop-
ment. Most exposable genes are HLA-DRBI, PTPN22, TNFα, and PYCARD which 
mutate because of unbalancing in environmental factors. This study updates the 
information that Non- Steroidal anti-inflammatory drugs, Heat therapy, Chloroquine, 
and sulfasalazine show good results in the treatment of PR. Although many studies 
have validated these emerging therapies, still there is a need for further research to 
figure out their efficacy and precision. Side effects of these drugs and therapies must 
be considered before clinical applications for achieving stunning gains in the future. 
Additionally, these summarized genes might be capable of improving the therapeutic 
inventions for PR hence will serve as a significant pioneer for researchers who wants 
to identify the associative pathways involve in the pathogenesis of PR.
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